Press release
Raynaud's Disease Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2024 | Gesynta Pharma, United Therapeutics, Vicore Pharma, Arena Pharmaceuticals
Raynaud's Disease Clinical Trials, Key Companies, Emerging Therapies
Request for a sample report @ https://www.delveinsight.com/report-store/raynauds-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Raynaud's Disease Pipeline Report
Over 5+ Raynaud's Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Raynaud's Disease market would significantly increase market revenue.
Leading Raynaud's Disease companies developing novel drug candidates to improve the Raynaud's Disease treatment landscape include Gesynta Pharma, United Therapeutics, and others.
Promising Raynaud's Disease pipeline therapies in various stages of development include GS 248, Treprostinil, and others.
Raynaud's Disease Overview
Raynaud's phenomenon is a condition that leads to decreased blood flow to the fingers. In some cases, it also affects the ears, toes, nipples, knees, or nose, causing reduced blood flow in these areas. This occurs due to spasms of the blood vessels, which are triggered by cold, stress, or emotional upset. Raynaud's can occur on its own, known as the primary form, or it may be associated with other diseases, known as the secondary form. The exact cause of Raynaud's is unknown, but it is possible that some blood disorders may contribute to the condition by increasing blood thickness. This could be due to an excess of platelets or red blood cells, or special receptors in the blood that control the narrowing of blood vessels may be more sensitive.
Symptoms can vary from person to person, but common signs include:
- Fingers that turn pale or white, then blue when exposed to cold or during stress or emotional upset, and then red when the hands are warmed.
- Hands that may become swollen and painful when warmed.
- Sores on the finger pads.
- In severe cases, gangrene in the fingers, which can lead to infection or the need for amputation, although this is rare.
Treatment for Raynaud's phenomenon depends on the symptoms, age, and general health of the individual, as well as the severity of the condition. While there is no cure for Raynaud's phenomenon, it can be managed with proper treatment.
Complications of Raynaud's phenomenon are rare but can include sores on the finger pads, which may progress to gangrene. In rare cases, gangrene may lead to finger amputation. For most people living with Raynaud's, it is more of an inconvenience than a serious problem. Avoiding triggers, primarily cold, can help reduce the spasms that lead to symptoms. If there is an underlying cause, such as scleroderma or lupus, managing the attacks may be more challenging. Managing Raynaud's includes avoiding cold, dressing warmly, and stopping smoking.
Raynaud's Disease Emerging Drugs
GS 248: Gesynta Pharma
GS-248 is Gesynta Pharma's most advanced drug candidate, currently in clinical development as a potential treatment of Raynaud's phenomenon. Gesynta Pharma is currently conducting a placebo-controlled clinical study in order to document the safety and efficacy profile of GS-248 during a four-week-treatment in circa 80 patients. The participants have been diagnosed with systemic sclerosis and exhibit recurrent Raynaud's phenomenon. The study is primarily tracking patients' symptoms, including the frequency of Raynaud attacks, but also documenting digital blood flow as well as inflammatory biomarkers. The study, is conducted in four European countries, is coordinated by the University of Manchester Centre for Musculoskeletal Research.
Treprostinil: United Therapeutics
Treprostinil is an investigational drug being developed by United Therapeutics. Currently, the drug is in Early Phase I for the treatment of Raynaud's phenomenon. Treprostinil, basically acts as a platelet aggregation inhibitor.
Discover more about the emerging Raynaud's Disease drugs @ https://www.delveinsight.com/sample-request/raynauds-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Raynaud's Disease Key Companies
Gesynta Pharma
United Therapeutics
Raynaud's Disease Pipeline Therapies
GS 248
Treprostinil
Raynaud's Disease Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Raynaud's Disease Pipeline Report
Coverage: Global
Key Raynaud's Disease Companies: Gesynta Pharma, United Therapeutics, and others
Key Raynaud's Disease Pipeline Therapies: GS 248, Treprostinil, and others
Find out more about the Raynaud's Disease treatment options in development @ https://www.delveinsight.com/sample-request/raynauds-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Raynaud's Disease Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2024 | Gesynta Pharma, United Therapeutics, Vicore Pharma, Arena Pharmaceuticals here
News-ID: 3634786 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Raynaud
Raynauds Disease Market is Expected to Show a Healthy Growth Rate During the Stu …
DelveInsight's "Raynauds Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Raynauds Disease, historical and forecasted epidemiology as well as the Raynauds Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Download Sample Report to know more @ https://www.delveinsight.com/sample-request/raynauds-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Raynauds Disease Overview
Raynaud's phenomenon is an episodic, exaggerated vascular response in which digital arteries constrict or spasm in response…
Tableware Market covering sales outlook, demand forecast & up-to-date key trends …
The global tableware market is expected to reach a valuation of US$ 44.5 Bn by 2032, with sales growing at a 5.6% CAGR over the forecast period.
Changing purchasing behavior influenced by the developing domestic segment and increasing urbanization will drive the sales of tableware. People in cities are progressively adopting a western lifestyle in several emerging economies, driving the tableware demand.
The tableware market has grown significantly as…
Iloprost Drugs Market Is Booming Worldwide 2021-2028 | Actelion Pharmaceuticals, …
Iloprost is a drug used for treating diseases such as pulmonary arterial hypertension, scleroderma, Raynaud syndrome, and other conditions where constriction in blood vessels and improper blood flow in tissues is found. The trade name of the drug is Ventavis or Ilomedine. Iloprost, which received approval by the U.S. Food and Drug Administration (FDA) in 2004 for pulmonary arterial hypertension.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3284
Iloprost dilates the narrowed blood vessels…
COVID-19 Impact on Raynauds Phenomenon Management Market Research, Size, Growt …
Raynauds Phenomenon Management Market is expected to grow significantly over next few years and generate considerable market for Raynauds Phenomenon Management .
Market Report Expert has recently published a research report titled, “Raynauds Phenomenon Management Market Outlook and Statistics, 2020-2026". The report has been prepared by experienced and knowledgeable market analysts, researchers, market experts, and key option leaders within Raynauds Phenomenon Management market. It is a remarkable collecting conclusion and analysis…
MODERN PRINCESS LANVIN NEW LAUNCH
THE INSPIRATION
With this new fragrance, Lanvin explores a new, highly contemporary vision of a woman: one who lives in mysterious ways, one who accepts the hidden, unmentionable facet of her actions, a rebellious adventurer.
Free-spirited, she lives the life of a disarmingly modern princess, of one who breaks rules in general, and rules of romance in particular. Glamorous, untamed and fiercely sensual, she uses her own free will, playing with…
